Background. Recovery of dialysis-independent renal function in long-term dialysis patients has not been studied extensively. The aim of this study was to investigate the effect of dialysis modality on the likelihood, timing and durability of recovery of dialysis-independent renal function. Methods. The study reviewed all patients in Australia and New Zealand who commenced dialysis for treatment of end-stage renal disease (ESRD) between 1963 and 2006. Dialysis modality was assigned at 90 days. A supplementary analysis was also conducted using a contemporary cohort that included data on comorbidities, smoking and eGFR at dialysis onset. Results. During the study period, 15 912 individuals received peritoneal dialysis (PD) and 23 658 received haemodialysis (HD). Renal recovery occurred in 176 (1.1%) PD and 244 (1.0%) HD patients. Using multivariate Cox proportional hazards regression analyses, dialysis modality was not independently predictive of time to renal recovery (HR 0.92, 95% CI 0.76-1.13, P = 0.4). Recovery was significantly more likely in patients with higher baseline eGFR, with no hypertension or peripheral vascular disease, and with certain causes of kidney failure (autoimmune renal disease, haemolytic uraemic syndrome, interstitial nephritis, obstructive uropathy, paraproteinaemia and renovascular nephrosclerosis). Recovery was less likely in Maori/Pacific Islanders and polycystic kidney disease. Among patients who recovered, 328 (78%) subsequently experienced renal death, mostly within the first year. The duration of renal recovery was not associated with initial dialysis modality (OR 0.82, 95% CI 0.50-1.32). Conclusions. Dialysis modality is not associated with the likelihood, timing or durability of spontaneous recovery of dialysis-independent renal function in patients thought to have ESRD.
Introduction
Recovery of dialysis-independent renal function in patients receiving renal replacement therapy (RRT) for end-stage (i.e. presumed irreversible) renal disease (ESRD) has been reported to occur in 0.3-8% of patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Renal recovery has been associated with older age, European descent or white race, cortical necrosis, renovascular disease, autoimmune renal disease (including scleroderma), paraproteinaemia, malignant hypertension and haemolytic uraemic syndrome in previous studies. Certain factors have been associated with a reduced rate of renal recovery, including Polynesian, Aboriginal and Torres Straight Island descent, diabetic nephropathy and polycystic kidney disease [4, 6, 7, 9, 11] . Some authors have demonstrated an increased incidence of renal recovery in patients receiving peritoneal dialysis (PD) compared with haemodialysis (HD) [3, 5, 8, 9] , but this is not a universal finding [4, 6] .
The factors influencing recovery of renal function are not well understood. Previous reports have been based on cohort studies with significant limitations. Many were singlecentre studies with small sample sizes [1] [2] [3] [4] [5] 8, 13] , examined only one dialysis modality [1, 2, 7, 11, 13] or were based on historical cohorts that may not reflect current dialysis practice [1] [2] [3] [4] [5] [6] [7] . Some excluded patients with incomplete data or only included patients with particular renal diseases [6, 8, 12] or who had previously undergone renal transplantation [1, 2] . Most studies did not consider non-renal comorbidities (such as smoking status, body habitus and cardiovascular disease) in their analyses. Furthermore, there is concern that results from many of these studies may have been affected by ascertainment bias or informative censoring.
While dialysis modality for some patients is mandated by specific clinical factors, in most cases the modality is determined by the preference or enthusiasm of the patient or clinician. It is important to know whether there are real differences in patient outcome determined by the choice of dialysis modality and specifically whether modality affects the likelihood of renal recovery or shortens the period of dialysis dependence. This is particularly the case in individuals who might otherwise receive early renal transplantation or who have conditions that are associated with an increased rate of renal recovery. The aim of the present study was to investigate the effect of dialysis modality on the likelihood, timing and durability of recovery of dialysis-independent renal function in the entire Australian and New Zealand dialysis population, using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry.
Patients and methods

Patient population
The cohort study included all patients with end-stage renal disease (ESRD) enrolled in the ANZDATA registry, who commenced dialysis between 15 May 1963 and 31 December 2005, and remained on dialysis for at least 90 days. All patients who entered into the ANZDATA registry were considered by their treating nephrologists to have ESRD and therefore thought to require long-term RRT at the time they were enrolled in the registry.
Dialysis modality was assigned at 90 days following commencement of RRT. The primary outcomes examined were recovery of dialysisindependent renal function and time from PD commencement to recovery of renal function. Recovery of dialysis-independent renal function was considered to have occurred if the treating renal unit had recorded that the patient had recovered renal function and completed dialysis therapy. The onset of recovery was defined as the date of the last dialysis treatment. A secondary outcome measure was time to renal death (patient death or recommencement of RRT) following recovery of dialysis-independent renal function.
For potentially related comorbidities, 'Suspected' was combined with 'Yes' for analyses. Dialysis vintage was determined by the dialysis commencement date: pre CAPD era (15 May 1963 to 31 March 1976; patients receiving intermittent PD or HD only), second decade (1 April 1976 to 31 March 1986), third decade (1 April 1986 to 31 March 1996) and fourth decade (1 April 1996 to 31 December 2005). Initial GFR was determined from serum creatinine at initiation of dialysis, patient age and gender, using the four-variable MDRD equation [14] and expressed as mL/min/1.73 m 2 . Body mass index (BMI) was calculated from weight/height 2 and expressed in kg/m 2 .
Statistical analysis
The results were expressed as frequencies and percentages for categorical variables, mean ± standard deviation for continuous variables and median (interquartile range; IQR) for non-parametric data. Baseline data were compared between patients receiving HD and PD and between patients who recovered renal function and those who did not. Dichotomous and categorical data were compared using chi-square tests. Continuous parametric data were compared using two-tailed unpaired t-tests. Continuous non-parametric data were compared using Mann-Whitney tests. Time to renal functional recovery was evaluated by Kaplan-Meier and multivariate Cox proportional hazards survival analyses. The covariates included in the model for the entire cohort were age, gender, racial origin, dialysis modality, ESRD cause and vintage. A supplementary analysis was also conducted using a contemporary cohort that included data on comorbidities, including BMI, smoking status, history of hypertension, cerebrovascular disease, ischaemic heart disease, diabetes, peripheral vascular disease and calculated GFR at dialysis onset. In view of the significant changes in dialysis practice over time, the influence of dialysis modality on renal recovery was analysed in each vintage separately as a sensitivity analysis. Adjusted survival curves were estimated using the Cox average covariate method, which calculates predicted survival probabilities at the mean levels of the covariates. Data were censored at the time of death, renal transplantation or end of study (31 December 2005). The predictors of subsequent loss of recovered renal function were evaluated by multivariate logistic regression. Data were analysed using the software package SPSS for Mac OSX release 13.0 (SPSS Inc., North Sydney, Australia). P-values <0.05 were considered statistically significant.
Results
Patient characteristics
Between 15 May 1963 and 31 December 2006, 39 570 individuals started dialysis for end-stage renal failure and remained on treatment for at least 90 days. At 90 days, 23 658 were receiving HD and 15 912 were receiving PD. They were followed up for a mean of 5.5 person-years (range 91 days to 39 years). The baseline characteristics of these individuals are displayed in Table 1 .
A total of 420 (1.1%) individuals had recovery of renal function, 244 (1.0%) individuals on HD and 176 (1.1%) patients on PD (P = 0.4). The median time to recovery was not significantly different between patients treated with HD (303 days, IQR 155-501 days) and those treated with PD (333 days, IQR 192-609 days, P = 0.1). The rate of renal recovery did not change when analysis was repeated including only patients starting dialysis after 31 December 1995 (i.e. last 10 years).
Predictors of renal function recovery
Dialysis modality at 90 days was not associated with time to recovery of dialysis-independent renal function on univariate analysis (log rank 0.98, P = 0.3). Using multivariate Cox proportional hazards model analysis for the entire cohort, dialysis modality was not independently associated with time to renal function recovery (HR 0.92, 95% CI 0.76-1.13, P = 0.4, Table 2, Figure 1 ). Renal recovery was significantly more likely in the setting of autoimmune renal disease, renal cortical necrosis, haemolytic uraemic syndrome, interstitial nephritis, obstructive uropathy, paraproteinaemia and renovascular nephrosclerosis (Table 2, Figure 2 ). Renal recovery was less likely in Maori and Pacific Islanders and patients with autosomal dominant polycystic kidney disease (Table 2) . Sex, age and vintage were not significantly associated with renal recovery. Dialysis modality at 90 days was not independently associated with renal recovery in each of the four vintages studied For patients on peritoneal dialysis, the probability of renal recovery was not influenced by sub-modality (automated versus continuous ambulatory peritoneal dialysis HR 0.90, 95% CI 0.70-1.15). Similar analyses could not be performed for haemodialysis, since the ANZDATA Registry does not collect information about haemodialysis sub-modality (including haemodialfiltration).
Supplementary analysis using a more contemporary cohort in which complete data were available on comorbidities (n = 17851) revealed similar results (Table 3 ). In particular, dialysis modality was not significantly associated with renal function recovery (HR 1.21, 95% CI 0.84-1.50). The development of dialysis-independent renal function was again associated with Maori and Pacific Islander racial origin and the same ESRD causes as previously (except for a lower probability of renal recovery in analgesic nephropathy). In addition, renal recovery was associated with a higher eGFR at dialysis commencement and was more likely in the absence of peripheral vascular disease and hypertension. Renal recovery was not significantly associated with BMI, smoking status, chronic lung disease, coronary artery disease, cerebrovascular disease or diabetes mellitus. In view of the potenatial limitations of using eGFR as a measure of renal function, a sensitivity analysis was performed by not including eGFR in the model. Using this approach, dialysis modality was still not predictive of renal recovery (HR 0.94, 95% CI 0.84-1.07). Another potential issue was the pos- sibility of informative censoring due to the slightly higher rate of renal transplantation in the PD group compared with the HD group (2.6 versus 2.2 per 100 patient-years, respectively, incident rate ratio 0.86, 95% CI 0.82-0.90). A sensitivity analysis was therefore performed in which all patients who underwent transplantation were treated in the analysis as if they had experienced spontaneous recovery of renal function. Using this approach, dialysis modality was not associated with recovery of dialysis-independent renal function (HR 1.00, 95% CI 0.92-1.08). PD0-HD90 HR 0.85, 95% CI 0.48-1.51; PD0-PD90 HR 0.90, 95% CI 0.71-1.14; HD0-HD90 reference) (Figure 3) . Similar findings were observed in the contemporary cohort (HD0-PD90 HR 1.70, 95% CI 1.11-2.59; PD0-HD90 HR 0.68, 95% CI 0.24-1.93; PD0-PD90 HR 0.86, 95% CI 0.57-1.32; HD0-HD90 reference). To assess the contribution of late referral to these findings, a supplementary analysis was performed in 25 809 patients in whom data Referral to a renal unit more than 3 months before commencing dialysis for ESRD was independently associated with a lower probability of renal recovery (HR 0.67, 95% CI 0.59-0.76).
Duration of dialysis-independent renal function following recovery
Among the 420 individuals who experienced return of dialysis-independent renal function, 78% subsequently experienced renal death, consisting either of death (n = 90 or 21%) or return to RRT (n = 238 or 57%). Patient death after renal recovery ranged from 12 days to 9.6 years, with a median of 309 days and an interquartile range of 153-598 days. Ninety-two individuals were alive with dialysisindependent renal function at the close of the study. As data on patients no longer receiving RRT were not reliably collected by the ANZDATA Registry (and therefore complete capture of all deaths could not be assured), no further analyses of mortality in patients who experienced recovery of renal function were able to be performed. Of the 238 patients who recovered renal function and then subsequently returned to RRT, 155 (65%) received HD, 79 (33%) received PD and 4 (2%) received a renal transplant. Eighty-six percent of patients who previously received HD at Day 90 returned to HD when they lost their recovered renal function, whilst 59% of patients initially treated with PD returned to PD (P < 0.001). The median (IQR) duration of recovered renal function prior to return to RRT was 420 (153-1029) days for HD patients and 385 (175-842) days for PD patients (P = 0.7) (Figure 4 
Discussion
To the best of our knowledge, the present investigation represents the largest examination of spontaneous recovery of dialysis-independent renal function in dialysis patients. The major finding of the study was that choice of initial dialysis modality (defined as modality at 90 days) had no relationship with the rate, timing or durability of renal recovery. These results are similar to those of the Michigan Kidney Registry study, which evaluated 7404 patients starting treatment for ESRD between 1976 and 1985 [6] . Recovery of renal function was observed in 211 (2.8%) patients, but the relative rates of recovery were not significantly different between patients managed with PD versus those treated with HD following adjustment for age, sex, race and year of ESRD (adjusted odds ratio 0.82, P = NS). Unlike the present study, however, patients treated with dialysis for less than 3 months were included, although patients with diagnoses of acute tubular necrosis, cortical necrosis and drug-induced renal failure as their primary cause of renal failure were excluded. The extrapolation of results of studies of dialysis therapies in the 1970s and early 1980s to contemporary nephrologic practice is also questionable. Michel et al. [4] similarly examined 410 ESRD patients treated between 1983 and 1988 and observed a renal function recovery rate of 4.5% in 198 PD patients and 3.2% in 212 HD patients; these differences did not achieve statistical significance. However, the authors included patients who were maintained on dialysis for less than 3 months, such that the possibility of underlying or superimposed acute kidney injury could not be excluded. Furthermore, their dialysis population had a lower rate of polycystic kidney disease compared to the ANZDATA population and a higher rate of myeloma and interstitial nephritis, which may have contributed to their higher observed rate of renal functional recovery.
In contrast, several studies have observed higher renal function recovery rates with PD than with HD [3, 5, 9] . Goldstein et al. [9] reported dialysis-independent recovery in 308 (1.6%) of 19 462 HD patients in New England and New Haven centres (1993-99) compared with 29 (2.4%) of 1200 PD patients in New Haven (1979-99) (P < 0.05). The findings of this study were limited by selection bias (as evidenced by the gross imbalance in numbers of patients selecting PD versus HD), lack of adjustment for demographic and clinical characteristics, vintage bias and centre bias. Indeed, a sub-analysis of ESRD patients receiving dialysis in New England between 1993 and 1998 demonstrated no significant difference in renal functional recovery rates between PD (2.1%) and HD (1.6%).
Canacarini and co-workers [3] also reported a higher renal recovery rate in PD patients (6 of 75 or 8%) compared with HD patients (1 of 75 or 1.2%), although neither the term 'ESRD' nor the criteria for discontinuing dialysis was defined. Using an ESRD definition of a combination of compatible clinical findings and/or a creatinine clearance of ∼5 mL/min, Rottembourg et al. [5] observed that 10 (3.3%) of 300 PD patients recovered renal function (creatinine clearance > 12 mL/min) compared with 4 (0.8%) of 495 HD patients (P < 0.05). Patients on dialysis for less than 3 months were excluded. The apparent disparity in results between this study and the present one may be explained by the fact that the former study covered a limited early vintage and was confined to a single centre.
A novel finding of our study was that patients who converted from HD at Day 0 to PD by Day 90 were significantly more likely to experience renal recovery than those who switched modality from PD to HD or those who remained on either PD or HD for the first 90 days. This finding may reflect patient factors, such as acuteness of presentation of kidney disease, although adjustment for both ESRD cause and late referral did not appreciably alter the results. Bias by indication may have been operative since it is possible that the presence or absence of residual kidney function was a factor in physician choice of modality, transferring to PD if preserved. Alternatively, it is also possible that early changing of modality from HD to PD directly improves the probability of renal function recovery, although this seems less likely given that renal recovery was not associated with dialysis modality at either Day 0 or Day 90.
Similar to the findings of a previous ANZDATA Registry analysis of incident PD patients [11] , we observed that recovery of dialysis-independent renal function was significantly more likely in the setting of particular causes of ESRD (autoimmune renal disease, haemolytic uraemic syndrome, interstitial nephritis, obstructive uropathy, paraproteinaemia and renovascular nephrosclerosis) and less likely in Maori and Pacific Islanders and patients with autosomal dominant polcystic kidney disease. The observation that ESRD cause predicts renal recovery is in keeping with the reports of other investigators [6, 7] .
Another novel aspect of the present study was the analysis of the durability of renal recovery in ESRD patients. In many cases where individuals recovered sufficient renal function to be able to discontinue dialysis, the duration of dialysis independence was only temporary with half of all patients returning to dialysis or dying within a year. This outcome was not associated with the dialysis modality employed at Day 0 and/or Day 90. Since the ANZDATA Registry does not continue to collect information on patients who permanently cease RRT, it was not possible to determine precise patient survival data, and therefore, the survival figures reported in our study may represent an overestimate. Nevertheless, the apparently high rate of early patient death or return to RRT after recovery of renal function raises questions about the appropriateness of discontinuing RRT in a significant proportion of these patients under such circumstances. In contrast, Sekkarie and co-workers [6] observed a longer duration of renal survival following renal function recovery (1-year renal survival 75% versus 40% in our study). This difference may be potentially explained by the fact that the Michigan study considered death from causes other than renal failure as 'lost to follow up' and censored as such. In the Michigan study, modality of dialysis therapy was not associated with the rate of relapse of ESRD, although that study was not adequately powered to address this question.
The strengths of the present investigation lie in its large cohort size and the robustness of the findings, i.e. the primary outcome remained consistent despite repeated analysis using different statistical techniques and adjusting for demographic characteristics, BMI, smoking, comorbid illnesses and vintage. Comparable results were also obtained regardless of whether the entire cohort or a more contemporary cohort was analysed. Patients receiving dialysis for <90 days were excluded to minimize the possibility of acute kidney injury rather than ESRD. Since we included all centres across both countries, we avoided the bias associated with reports from single centres, which may have had specific interest and expertise in a particular dialysis modality that in turn influenced renal function recovery outcomes. Across Australia and New Zealand, PD is used to treat approximately between 20 and 40% of prevalent dialysis patients, depending on region. Although usage varies, both modalities are available in all major treatment centres. Thus, selection bias towards PD due to only the 'best' patients with the highest chance of renal recovery being treated with this modality, or treatment only occurring in units with particular expertise, was likely to be less than that in countries with a smaller prevalent PD population.
Nevertheless, the study had a number of potentially significant limitations. Selection bias could not be excluded since there were significant differences in the characteristics of patients treated with PD versus HD. Of the factors demonstrated in this study to have an effect on renal recovery, PD patients were more likely to be of Maori or Pacific Island origin, have a history of analgesic nephropathy or renovascular disease, have comorbidities and less likely to have polycystic kidney disease or paraprotein nephropathy than HD patients. PD patients had a marginally higher renal function at initiation than HD patients (although this difference was not clinically significant). While we were able to adjust for reported comorbidities on a categorical basis, ANZDATA does not collect information about the severity of comorbidities, such that it is difficult to entirely exclude the possibility of residual confounding. Vintage and ascertainment biases may also have conceivably influenced our findings due to variations over time and between different renal units with respect to diagnosing ESRD and accepting patients onto RRT programmes (with subsequent recording on the ANZDATA Registry). Although dialysis modality was not associated with renal recovery when each of the four dialysis vintages was separately analysed, the possibility of a type 2 statistical error could not be confidently excluded. Bias by indication may also have been introduced by variability in the vigour with which clinicians pursued a diagnosis of renal function recovery and took patients off dialysis treatment according to certain patient characteristics (for example, age or renal disease type), dialysis modality or the location of treatment. Survival bias may also have been operative, since certain groups of patients (for example, diabetics) may have been more likely to die before renal function recovery occurred. Finally, since ANZDATA only collects information on individuals whilst they are receiving RRT, it is possible that not all deaths were ascertained by ANZDATA during the period of time that patients had recovered dialysis-independent renal function. In spite of these potential biases, it is unlikely that the impact of dialysis modality on renal recovery in ESRD will be better addressed than by registry studies.
In conclusion, the present study demonstrated that recovery of dialysis-independent renal function is rare, generally short-lived and primarily determined by underlying primary renal disease. Dialysis modality does not appreciably influence the likelihood, timing or durability of renal recovery.
